Antisoma plc (ASM) - Financial and Strategic SWOT Analysis Review

Date: November 7, 2012
Pages: 34
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: A9396BE3E3EEN
Leaflet:

Download PDF Leaflet

Antisoma plc (ASM) - Financial and Strategic SWOT Analysis Review
  • Abstracts
  • Contents
Summary

Antisoma plc (Antisoma) is a biopharmaceutical company specialized in novel anti-cancer drugs. The company's development pipeline is filled through its acquisition of promising new product candidates from academic or cancer research institutions. Antisoma's principal activity involves the preclinical and clinical development of its drug candidates related to Oncology. Its product pipeline consists of AS1411 (an aptamer based on a short piece of DNA or RNA), for a range of solid and blood cancer cell lines; DCAMs (Dendritic Cell Autoimmune Modulators), for auto-immune conditions such as inflammatory bowel diseases and rheumatoid arthritis; and PPM1D a phosphates inhibitor expressed in many forms of cancer. The company is headquartered in London, the UK.

Antisoma plc Key Recent Developments

Mar 09, 2011: Antisoma Announces Corporate Restructuring
Mar 02, 2011: Antisoma Names Grahame Cook And Michael Bretherton To Board
Feb 28, 2011: Antisoma Announces Board Changes
Feb 08, 2011: Antisoma Reports Net Loss Of £15.4m For Six Months Ended December 31, 2010

This comprehensive SWOT profile of Antisoma plc provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY

Antisoma plc - Key Facts
Antisoma plc - Key Employees
Antisoma plc - Major Products and Services
Antisoma plc - Pharmaceutical Pipeline Products Data
Antisoma plc, Pipeline Products by Therapy Area
Antisoma plc, Pipeline Products by Development Phase
Antisoma plc - History
Antisoma plc - Company Statement
Antisoma plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Antisoma plc - Business Description
Antisoma plc - Corporate Strategy
Antisoma plc - SWOT Analysis
SWOT Analysis - Overview
Antisoma plc - Strengths
Strength - Focused Research and Development Initiatives
Strength - Partnerships and Collaborations
Antisoma plc - Weaknesses
Weakness - History of Losses
Weakness - Discontinuation of Product Development
Antisoma plc - Opportunities
Opportunity - Growing Prospects: Oncology
Opportunity - Restructuring Initiatives
Opportunity - Growth Potential: Musculoskeletal Therapeutics
Antisoma plc - Threats
Threat - Stringent Government Regulations
Threat - Uncertain R&D Outcomes
Threat - Competitive Landscape
Antisoma plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Antisoma plc, Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
Antisoma plc, Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012
Antisoma plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Antisoma plc, Recent Developments
Mar 09, 2011: Antisoma Announces Corporate Restructuring
Mar 02, 2011: Antisoma Names Grahame Cook And Michael Bretherton To Board
Feb 28, 2011: Antisoma Announces Board Changes
Feb 08, 2011: Antisoma Reports Net Loss Of ?15.4m For Six Months Ended December 31, 2010

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Antisoma plc, Key Facts
Antisoma plc, Key Employees
Antisoma plc, Major Products and Services
Antisoma plc, Number of Pipeline Products by Therapy Area
Antisoma plc, Number of Pipeline Products by Development Stage
Antisoma plc, Pipeline Products By Therapy Area and Development Phase
Antisoma plc, History
Antisoma plc, Subsidiaries
Antisoma plc, Key Competitors
Antisoma plc, Ratios based on current share price
Antisoma plc, Annual Ratios
Antisoma plc, Interim Ratios
Antisoma plc, Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
Antisoma plc, Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012
Antisoma plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Antisoma plc, Pipeline Products by Therapy Area
Antisoma plc, Pipeline Products by Development Phase
Antisoma plc, Performance Chart (2007 - 2011)
Antisoma plc, Ratio Charts
Antisoma plc, Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
Antisoma plc, Pharmaceuticals & Healthcare, Deals by Type, 2006 to YTD 2012

Ask Your Question

Antisoma plc (ASM) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: